59 results on '"Usmani, Saad Z"'
Search Results
2. Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
- Author
-
Martin, Tom, Usmani, Saad Z., Schecter, Jordan M., Roccia, Tito, Jackson, Carolyn C., Deraedt, William, Yeh, Tzu-min, Banerjee, Arnob, Pacaud, Lida, Garrett, Ashraf, Bartlett, Meaghan, Haltner, Anja, Van Sanden, Suzy, Diels, Joris, Valluri, Satish, and Samjoo, Imtiaz A.
- Subjects
- *
MULTIPLE myeloma , *TREATMENT effectiveness , *MONOCLONAL antibodies , *DEEP brain stimulation , *PROGRESSION-free survival , *PROTEASOME inhibitors , *ODDS ratio , *BRAIN stimulation - Abstract
This study used the latest available data cuts from the CARTITUDE-1 and KarMMa clinical trials to update previously published matching-adjusted indirect treatment comparisons (MAICs) assessing the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the FDA-approved idecabtagene vicleucel (ide-cel) dose range of 300 to 450 × 106 CAR-positive T-cells in the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed). MAICs were performed with the latest available individual patient data for cilta-cel (CARTITUDE-1) and published summary-level data for ide-cel (KarMMa). The analyses included treated patients from CARTITUDE-1 who satisfied the eligibility criteria for KarMMa. The MAIC adjusted for unbalanced baseline covariates of prognostic significance identified in the literature and by clinical expertise. Comparative efficacy was assessed for overall response rate (ORR), complete response or better (≥CR) rate, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Cilta-cel was associated with statistically significantly improved ORR (odds ratio [OR]: 94.93 [95% confidence interval [CI]: 21.86, 412.25; p <.0001]; relative risk [RR]: 1.34), ≥CR rate (OR: 5.65 [95% CI: 2.51, 12.69; p <.0001]; RR: 2.23), DoR (hazard ratio [HR]: 0.52 [95% CI: 0.30, 0.88; p =.0152]), PFS, (HR: 0.38 [95% CI: 0.24, 0.62; p <.0001]), and OS (HR: 0.43 [95% CI: 0.22, 0.88; p =.0200]) compared with ide-cel. These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes over longer follow-up and highlight its therapeutic potential in triple-class exposed RRMM patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
- Author
-
Usmani, Saad Z, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Gavriatopoulou, Maria, Oriol, Albert, Rabin, Neil, Nooka, Ajay, Qi, Ming, Beksac, Meral, Jakubowiak, Andrzej, Ding, Bifeng, Zahlten-Kumeli, Anita, Yusuf, Akeem, and Dimopoulos, Meletios
- Subjects
- *
MULTIPLE myeloma , *DARATUMUMAB , *PROGRESSION-free survival , *SURVIVAL analysis (Biometry) , *SEPTIC shock , *THERAPEUTIC use of antineoplastic agents , *RESEARCH , *OLIGOPEPTIDES , *DEXAMETHASONE , *MONOCLONAL antibodies , *EVALUATION research , *DISEASE relapse , *COMPARATIVE studies - Abstract
Background: Despite recent advances in therapeutic options, there remains an unmet need for treating patients with relapsed or refractory multiple myeloma, especially in those previously exposed or refractory to lenalidomide. This updated efficacy and safety analysis from the phase 3 CANDOR study compared carfilzomib, daratumumab, and dexamethasone (KdD) with carfilzomib and dexamethasone (Kd) in patients with relapsed or refractory multiple myeloma.Methods: In this updated analysis of the randomised, multicentre, open-label, phase 3 CANDOR study, patients (aged ≥18 years) with relapsed or refractory multiple myeloma, at least a partial response to between one and three previous therapies, and Eastern Cooperative Oncology Group performance status of 0-2, were recruited from 102 medical centres globally and randomly assigned (2:1) by interactive voice or web response software to receive KdD or Kd. Participants were stratified by disease stage, previous proteasome inhibitor or anti-CD38 antibody exposure, and number of previous therapies. All patients received intravenous infusions of carfilzomib twice per week at 56 mg/m2 (20 mg/m2 on days 1 and 2 during cycle 1) on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients >75 years old). This analysis was a preplanned interim analysis for overall survival; however, at the time of data cutoff, overall survival data were not mature. The primary endpoint was progression-free survival. Here, we provide updated progression-free survival data, assessed centrally by Onyx Response Computer Algorithm in the intention-to-treat population, with 11 months additional follow-up. Adverse events were assessed in the safety population, which included all participants who received at least one dose of trial treatment. CANDOR is registered with ClinicalTrials.gov, NCT03158688, and is active but not recruiting.Findings: Between June 13, 2017, and June 25, 2018, 466 patients were enrolled, of whom 312 received KdD and 154 received Kd. At data cutoff (June 15, 2020), median follow-up was 27·8 months (IQR 25·6-29·5) for KdD and 27·0 months (13·2-28·6) for Kd. Median progression-free survival was 28·6 months (95% CI 22·7-not estimable [NE]) in the KdD group and 15·2 months (11·1-19·9) in the Kd group (hazard ratio 0·59 [95% CI 0·45-0·78], log-rank p<0·0001). Treatment-emergent adverse events in the safety population were consistent with the primary analysis. Grade 3 or worse treatment-emergent adverse events occurred in 268 (87%) patients in the KdD group and 116 (76%) in the Kd group; most commonly thrombocytopenia (76 [25%] vs 25 [16%], respectively), hypertension (65 [21%] vs 23 [15%]), pneumonia (54 [18%] vs 14 [9%]), and anaemia (53 [17%] vs 23 [15%]). Serious adverse events occurred in 194 (63%) patients with KdD and 76 (50%) with Kd. Adverse events leading to death occurred in 27 (9%) patients in the KdD group and seven (5%) in the Kd group; most commonly septic shock (five [2%] vs one (1%]) and pneumonia (four [1%] vs none). No new treatment-related deaths have occurred since the primary analysis.Interpretation: A clear, maintained progression-free survival benefit of KdD over Kd with longer follow-up was confirmed, making KdD an emerging standard-of-care for patients with relapsed or refractory multiple myeloma.Funding: Amgen and Janssen. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
4. Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma.
- Author
-
Martin, Tom, Usmani, Saad Z., Schecter, Jordan M., Vogel, Martin, Jackson, Carolyn C., Deraedt, William, Tian, Hong, Yeh, Tzu-min, Banerjee, Arnob, Pacaud, Lida, Garrett, Ashraf, Haltner, Anja, Cameron, Chris, Van Sanden, Suzy, Diels, Joris, Valluri, Satish, and Samjoo, Imtiaz A.
- Subjects
- *
TREATMENT effectiveness , *MULTIPLE myeloma , *OVERALL survival , *PROTEASOME inhibitors , *PROGRESSION-free survival , *RITUXIMAB - Abstract
This study estimated the comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus the approved idecabtagene vicleucel (ide-cel) dose range of 300–460 × 106 CAR-positive T-cells for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) who were previously treated with a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 monoclonal antibody (i.e. triple-class exposed) using matching-adjusted indirect treatment comparisons (MAICs). MAICs were performed with individual patient data for cilta-cel (CARTITUDE-1; NCT03548207) and published summary-level data for ide-cel (KarMMa; NCT03361748). Treated patients from CARTITUDE-1 who satisfied the eligibility criteria for KarMMa were included in the analyses. The MAIC adjusted for unbalanced baseline covariates of prognostic significance identified in the literature and by clinical expertise. Comparative efficacy was estimated for overall response rate (ORR), complete response or better (≥CR) rate, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Cilta-cel was associated with statistically significantly improved ORR (odds ratio [OR]: 94.93 [95% confidence interval [CI]: 21.86, 412.25; p <.0001]; relative risk [RR]: 1.34), ≥CR rate (OR: 5.49 [95% CI: 2.47, 12.21; p <.0001]; RR: 2.21), DoR (hazard ratio [HR]: 0.50 [95% CI: 0.29, 0.87; p =.0137]), and PFS (HR: 0.37 [95% CI: 0.22, 0.62; p =.0002]) when compared with ide-cel. For OS, the results were in favor of cilta-cel and clinically meaningful but with a CI overlapping one (HR: 0.55 [95% CI: 0.29, 1.05; p =.0702]). These analyses demonstrate improved efficacy with cilta-cel versus ide-cel for all outcomes, highlighting its therapeutic potential in patients with triple-class exposed RRMM. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study.
- Author
-
Usmani, Saad Z, Garfall, Alfred L, van de Donk, Niels W C J, Nahi, Hareth, San-Miguel, Jesus F, Oriol, Albert, Rosinol, Laura, Chari, Ajai, Bhutani, Manisha, Karlin, Lionel, Benboubker, Lotfi, Pei, Lixia, Verona, Raluca, Girgis, Suzette, Stephenson, Tara, Elsayed, Yusri, Infante, Jeffrey, Goldberg, Jenna D, Banerjee, Arnob, and Mateos, María-Victoria
- Subjects
- *
BISPECIFIC antibodies , *MULTIPLE myeloma , *CD3 antigen , *CYTOKINE release syndrome , *T cells , *RESEARCH , *IMMUNOGLOBULINS , *INTRAVENOUS therapy , *CLINICAL trials , *RESEARCH methodology , *CELL receptors , *MONOCLONAL antibodies , *CANCER relapse , *MEDICAL cooperation , *EVALUATION research , *TREATMENT effectiveness , *COMPARATIVE studies , *DOSE-effect relationship in pharmacology , *SUBCUTANEOUS injections - Abstract
Background: There is a need for novel therapies for relapsed or refractory multiple myeloma, and B-cell maturation antigen (BCMA) is a validated target. Teclistamab is a bispecific antibody that binds BCMA and CD3 to redirect T cells to multiple myeloma cells. The aim of the MajesTEC-1 study was to evaluate the safety, tolerability, and preliminary efficacy of teclistamab in patients with relapsed or refractory multiple myeloma.Methods: This open-label, single-arm, phase 1 study enrolled patients with multiple myeloma who were relapsed, refractory, or intolerant to established therapies. Teclistamab was administered intravenously (range 0·3-19·2 μg/kg [once every 2 weeks] or 19·2-720 μg/kg [once per week]) or subcutaneously (range 80-3000 μg/kg [once per week]) in different cohorts, with step-up dosing for 38·4 μg/kg or higher doses. The primary objectives were to identify the recommended phase 2 dose (part one) and characterise teclistamab safety and tolerability at the recommended phase 2 dose (part two). Safety was assessed in all patients treated with at least one dose of teclistamab. Efficacy was analysed in response-evaluable patients (ie, patients who received at least one dose of teclistamab and had at least one post-baseline response evaluation). This ongoing trial is registered with ClinicalTrials.gov, NCT03145181.Findings: Between June 8, 2017, and March 29, 2021, 219 patients were screened for study inclusion, and 157 patients (median six previous therapy lines) were enrolled and received at least one dose of teclistamab (intravenous n=84; subcutaneous n=73). 40 patients were administered the recommended phase 2 dose, identified as once per week subcutaneous administration of teclistamab at 1500 μg/kg, after 60 μg/kg and 300 μg/kg step-up doses (median follow-up 6·1 months, IQR 3·6-8·2). There were no dose-limiting toxicities at the recommended phase 2 dose in part one. In the 40 patients treated at the recommended phase 2 dose, the most common treatment-emergent adverse events were cytokine release syndrome in 28 (70%; all grade 1 or 2 events) and neutropenia in 26 (65%) patients (grade 3 or 4 in 16 [40%]). The overall response rate in response-evaluable patients treated at the recommended phase 2 dose (n=40) was 65% (95% CI 48-79); 58% achieved a very good partial response or better. At the recommended phase 2 dose, the median duration of response was not reached. 22 (85%) of 26 responders were alive and continuing treatment after 7·1 months' median follow-up (IQR 5·1-9·1). At the recommended phase 2 dose, teclistamab exposure was maintained above target exposure levels, and consistent T-cell activation was reported.Interpretation: Teclistamab is a novel treatment approach for relapsed or refractory multiple myeloma. At the recommended phase 2 dose, teclistamab showed promising efficacy, with durable responses that deepened over time, and was well tolerated, supporting further clinical development.Funding: Janssen Research & Development. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
6. Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.
- Author
-
Luo, Man (Melody), Usmani, Saad Z., Mateos, Maria‐Victoria, Nahi, Hareth, Chari, Ajai, San‐Miguel, Jesus, Touzeau, Cyrille, Suzuki, Kenshi, Kaiser, Martin, Carson, Robin, Heuck, Christoph, Qi, Ming, Zhou, Honghui, Sun, Yu‐Nien, and Parasrampuria, Dolly A.
- Subjects
- *
DARATUMUMAB , *THERAPEUTIC use of monoclonal antibodies , *THERAPEUTIC use of antineoplastic agents , *DRUG efficacy , *INVESTIGATIONAL drugs , *DISEASE incidence , *CANCER patients , *TREATMENT effectiveness , *MULTIPLE myeloma , *SUBCUTANEOUS infusions , *PATIENT safety - Abstract
We report the population pharmacokinetic (PK) and exposure‐response analyses of a novel subcutaneous formulation of daratumumab (DARA) using data from 3 DARA subcutaneous monotherapy studies (PAVO Part 2, MMY1008, COLUMBA) and 1 combination therapy study (PLEIADES). Results were based on 5159 PK samples from 742 patients (DARA 1800 mg subcutaneously, n = 487 [monotherapy, n = 288; combination therapy, n = 199]; DARA 16 mg/kg intravenously, n = 255 [all monotherapy, in COLUMBA]; age, 33‐92 years; weight, 28.6‐147.6 kg). Subcutaneous and intravenous DARA monotherapies were administered once every week for cycles 1‐2, once every 2 weeks for cycles 3‐6, and once every 4 weeks thereafter (1 cycle is 28 days). The subcutaneous DARA combination therapy was administered with the adaptation of corresponding standard‐of‐care regimens. PK samples were collected between cycle 1 and cycle 12. Among monotherapy studies, throughout the treatment period, subcutaneous DARA provided similar/slightly higher trough concentrations (Ctrough) versus intravenous DARA, with lower maximum concentrations and smaller peak‐to‐trough fluctuations. The PK profile was consistent between subcutaneous DARA monotherapy and combination therapies. The exposure‐response relationship between daratumumab PK and efficacy or safety end points was similar for subcutaneous and intravenous DARA. Although the ≤65‐kg subgroup reported a higher incidence of neutropenia, no relationship was found between the incidence of neutropenia and exposure, which was attributed, in part, to the preexisting imbalance in neutropenia between subcutaneous DARA (45.5%) and intravenous DARA (19%) in patients ≤50 kg. A flat relationship was observed between body weight and any grade and at least grade 3 infections. The results support the DARA 1800‐mg subcutaneous flat dose as an alternative to the approved intravenous DARA 16 mg/kg. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results.
- Author
-
Usmani, Saad Z., Mateos, Maria-Victoria, Hungria, Vania, Iida, Shinsuke, Bahlis, Nizar J., Nahi, Hareth, Magen, Hila, Cavo, Michele, Hulin, Cyrille, White, Darrell, De Stefano, Valerio, Fastenau, John, Slavcev, Mary, Heuck, Christoph, Qin, Xiang, Pei, Huiling, Masterson, Tara, Lantz, Kristen, and Gries, Katharine S.
- Subjects
- *
PATIENT satisfaction , *MULTIPLE myeloma , *CLINICAL trials , *CANCER treatment , *DARATUMUMAB - Abstract
Purpose: The phase III COLUMBA study evaluated daratumumab (DARA) intravenous (IV) and subcutaneous (SC) in patients with relapsed or refractory multiple myeloma. Here, we report patient-reported satisfaction with therapy (SWT) in COLUMBA. Methods: DARA IV or DARA SC was administered weekly (cycles 1–2), every 2 weeks (cycles 3–6), and every 4 weeks (cycles 7 +). Patients completed a modified version of the Cancer Therapy Satisfaction Questionnaire (CTSQ) at weekly (cycles 1–2) and monthly (cycles 3 +) intervals and at the end of treatment. Results for each item and the SWT domain score were summarized using descriptive statistics. The distribution of responses for individual items was calculated for each assessment. The proportion of patients for whom SWT domain score change from first assessment met or exceeded the minimally important difference (MID) of 5.9 points was calculated at each assessment time point. Results: Two-hundred fifty-nine patients were randomized to DARA IV and 263 to DARA SC. Mean scores for SWT domain questions were high and largely positive during treatment. Responses indicating positive perceptions of therapy were given by a numerically greater proportion of patients in the DARA SC group than the DARA IV group for most questions. Changes from the first assessment in SWT domain scores met or exceeded the MID for an average of ~ 40% of patients. Conclusion: In COLUMBA, modified CTSQ results suggest patients in the DARA SC group were more satisfied with their cancer therapy than those in the DARA IV group. Trial registration: ClinicalTrials.gov identifier NCT03277105. Registered September 8, 2107. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
8. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
- Author
-
Arnall, Justin R, Usmani, Saad Z, Adamu, Hawawu, Mishkin, Joseph, and Bhutani, Manisha
- Subjects
- *
THERAPEUTIC use of monoclonal antibodies , *DEXAMETHASONE , *ABDOMINAL pain , *COMBINATION drug therapy , *HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma , *THALIDOMIDE , *CARDIAC amyloidosis - Abstract
Systemic light-chain (AL) amyloidosis is a rare hematologic disorder where proteins infiltrate tissues leading to organ failure and death. Cardiac involvement, present in ∼70% of patients, determines stage and prognosis of the disease, with advanced involvement having a median survival of six months. The treatment of light-chain amyloidosis is directed at recovering organ function with therapeutic strategies following those of multiple myeloma with plasma cell-directed therapies. The use of single agent daratumumab has been reported in light-chain amyloidosis achieving rapid and deep responses. The combination of daratumumab, pomalidomide, and dexamethasone (DaraPomD) is particularly interesting for severe AL based on success in multiple myeloma. A 43-year-old female with light-chain amyloidosis and concomitant multiple myeloma presented with severe bowel dysmotility causing abdominal pain, anemia, and a 100-pound unintentional weight loss. A combination of cyclophosphamide, bortezomib, and dexamethasone was initiated but after five cycles her symptoms were progressing and therapy was switched to DaraPomD to optimize response. At the conclusion of two cycles she had achieved an amyloid complete-hematologic response, with her recurring ileus and abdominal pain significantly improved. Additionally, cardiac markers also suggested a rapid response without a common paradoxical worsening of congestive heart failure, and was overall well tolerated. Given the severe symptoms and refractory nature of our patient's disease DaraPomD was reasonable. With the tolerability and response seen, this patient experience supports a formal clinical trial evaluating the safety and efficacy of DaraPomD in light-chain amyloidosis. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Quadruplets come of age for newly diagnosed multiple myeloma.
- Author
-
Bhutani, Manisha and Usmani, Saad Z
- Subjects
- *
MULTIPLE myeloma , *QUADRUPLETS , *MONOCLONAL gammopathies , *PROGRESSION-free survival , *AUTOGRAFTS , *PLASMACYTOMA , *HEMATOLOGIC malignancies - Abstract
To say that the management of newly diagnosed multiple myeloma has changed in the past decade is a cliché. A pertinent question is whether the quadruplet therapy including daratumumab will replace the current triplet therapy and alter clinical practice to establish a new standard for transplant-ineligible, newly diagnosed multiple myeloma. 9 A Palumbo, F Gay, F Cavallo, Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. [Extracted from the article]
- Published
- 2020
- Full Text
- View/download PDF
10. Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.
- Author
-
Usmani, Saad Z., Khan, Imran, Chiu, Christopher, Foureau, David, Druhan, Lawrence J., Rigby, Katherine, Casneuf, Tineke, and Sasser, A. Kate
- Subjects
- *
MULTIPLE myeloma treatment , *MONOCLONAL antibodies , *T cells - Abstract
Background: Daratumumab, a human CD38 monoclonal antibody that has direct on-tumor and immunomodulatory mechanisms of action, demonstrated clinical benefit as monotherapy or in combination with established regimens in patients with multiple myeloma with one or more prior lines of therapy. Case presentation: A male patient, who was 70 years of age at the time of diagnosis of multiple myeloma in 2011, relapsed after five lines of therapy, including autologous stem cell transplantation. The patient's disease, which was considered high risk with a deletion of chromosome 17p, advanced quickly and was triple refractory 2 years after diagnosis leaving few treatment options. He was treated with daratumumab monotherapy in the SIRIUS clinical trial resulting in a stringent complete response and clearance of minimal residual disease. The duration of the patient's clinical response is now over 3.5 years without relapse, compared with a median of 7.6 months for similarly treated patients. The patient's immunophenotype revealed CD8+ T-cell expansion, clonal expansion of the T-cell receptor repertoire and decreases in regulatory T cells during daratumumab therapy, suggesting a robust adaptive immune response. This immune response was still present 32 months into daratumumab therapy. Conclusions: The results from this case report showed that a patient with advanced multiple myeloma, who had exhausted all treatment options with existing regimens, mounted an ongoing, deep and durable response to daratumumab monotherapy. Further investigation of the immunologic profile provided additional patient-level evidence of an immunomodulatory mechanism of action of daratumumab. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
11. Maintenance lenalidomide after transplantation: How much is enough?
- Author
-
Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *PATIENT management , *CANCER chemotherapy , *THALIDOMIDE , *CANCER research , *PATIENTS - Abstract
A longer duration of lenalidomide maintenance appears to improve survival outcomes. Patients who will benefit still cannot be distinguished from those who will not. See also pages 3831‐7. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
- Author
-
Usmani, Saad Z., Weiss, Brendan M., Plesner, Torben, Bahlis, Nizar J., Belch, Andrew, Lonial, Sagar, Lokhorst, Henk M., Voorhees, Peter M., Richardson, Paul G., Chari, Ajai, Sasser, A. Kate, Axel, Amy, Feng, Huaibao, Uhlar, Clarissa M., Jianping Wang, Khan, Imran, Ahmadi, Tahamtan, and Nahi, Hareth
- Subjects
- *
DRUG efficacy , *MULTIPLE myeloma treatment , *PROTEASOME inhibitors , *PROGRESSION-free survival , *IMMUNOSUPPRESSION , *ASPIRATION pneumonia - Abstract
The efficacy and favorable safety profile of daratumumab monotherapy in multiple myeloma (MM) was previously reported. An updated pooled analysis of 148 patients treated with daratumumab 16 mg/kg is presented. Data were combined from part 2 of a "first-in-human," phase 1/2 study of patients who relapsed after or were refractory to ⩾2 prior therapies and a phase 2 study of patients previously treated with ⩾3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or were double refractory. Among the pooled population, patients received a median (range) of 5 (2-14) prior lines of therapy, and 86.5% were double refractory to a PI and IMID. Overall response rate was 31.1%, including 13 very good partial responses, 4 complete responses, and 3 stringent complete responses. The median duration of response was 7.6 months (95% confidence interval [CI], 5.6-not evaluable [NE]). The median progression-free survival (PFS) and overall survival (OS) was 4.0 months (95% CI, 2.8-5.6) and 20.1 months (95% CI, 16.6-NE), respectively. When stratified by responders versus stable disease/minimal response versus progressive disease/NE, median PFS was 15.0 months (95% CI, 7.4-NE) versus 3.0 months (95% CI, 2.8-3.7) versus 0.9 months (95% CI, 0.9-1.0), respectively, and median OS was NE (95% CI, NE-NE) versus 18.5 months (95% CI, 15.1-22.4) versus 3.7 months (95% CI, 1.7-7.6), respectively. No new safety signals were identified. In this pooled dataset, daratumumab 16 mg/kg monotherapy demonstrated rapid, deep, and durable responses, with a clinical benefit that extended to patients with stable disease or better. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Post-protocol therapy and informative censoring in the CANDOR study - Authors' reply.
- Author
-
Usmani, Saad Z, Li, Chuang, Obreja, Mihaela, and Dimopoulos, Meletios
- Subjects
- *
CENSORSHIP , *AUTHORS , *STATISTICAL models - Published
- 2022
- Full Text
- View/download PDF
14. Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma.
- Author
-
Usmani, Saad Z., Sawyer, Jeffrey, Rosenthal, Adam, Cottler-Fox, Michele, Epstein, Joshua, Yaccoby, Shmuel, Sexton, Rachael, Hoering, Antje, Singh, Zeba, Heuck, Christoph J., Waheed, Sarah, Chauhan, Nabeel, Johann, Donald, Abdallah, Al-Ola, Muzaffar, Jameel, Petty, Nathan, Bailey, Clyde, Crowley, John, Van Rhee, Frits, and Barlogie, Bart
- Subjects
- *
MYELODYSPLASTIC syndromes , *ACUTE leukemia , *THALIDOMIDE , *HUMAN cytogenetics , *MICROGLOBULINS , *DISEASE risk factors - Abstract
Lenalidomide has been linked to myelodysplastic syndrome (MDS) after autotransplants for myeloma. Total therapy trials (TT; TT2-/+ thalidomide) and TT3 (TT3a with bortezomib, thalidomide; TT3b with additional lenalidomide) offered the opportunity to examine the contribution of .these immune-modulatory agents to MDS-associated cytogenetic abnormalities (MDS-CA) and clinical MDS or acute leukemia ("clinical MDS/AL"). Of 1080 patients with serial cytogenetic studies, MDS-CA occurred in 11% and clinical MDS/AL in 3%. Risk features of MDS-CA included TT3b, age ⩾65 years, male gender, levels of (J-2-microglobulin >5.5 mg/L, and multiple myeloma relapse. Clinical MDS/AL occurred less frequently in the control arm of TT2 and more often with TT3a and TT3b. Since MDS-CA often antedated clinical disease, periodic cytogenetic monitoring is recommended. Larger CD34 quantities should be collected upfront as the risk of MDS could be reduced by applying higher CD34 doses with transplant. Thus, treatment, host, and myeloma features could be linked to MDS development after therapy for this malignancy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
15. Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3.
- Author
-
Usmani, Saad Z., Mitchell, Alan, Waheed, Sarah, Crowley, John, Hoering, Antje, Petty, Nathan, Brown, Tracy, Bartel, Twyla, Anaissie, Elias, van Rhee, Frits, and Barlogie, Bart
- Subjects
- *
POSITRON emission tomography , *MULTIPLE myeloma treatment , *BONE metastasis , *PROGNOSIS , *GENE expression profiling - Abstract
Prognostic implications of 3 imaging tools, metastatic bone survey, magnetic resonance imaging, and positron emission tomography (PET), were evaluated in 2 con- secutive Total Therapy 3 trials for newly diagnosed myeloma. Data including PET at baseline and on day 7 of induction as well as standard prognostic factors were available in 302 patients of whom 277 also had gene expression profiling (GEP)- derived risk information. According to multivariate analysis, more than 3 focal lesions on day 7 imparted inferior overall survival and progression-free survival, overall and in the subset with GEP-risk data. GEP high-risk designation retained independent sig- nificance for all 3 end points examined. Thus, the presence of >3 focal lesions on day 7 PET follow-up may be exploited toward early therapy change, especially for the 15% of patients with GEP-defined high-risk disease with a median overall survival expectation of 2 years. This trial was registered at www.clinicaltrials.gov as #NCT00081939 and #NCT00572169. (Blood. 2013;121(10):1819-1823) [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
16. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
- Author
-
Usmani, Saad Z., Sexton, Rachel, Hoering, Antje, Heuck, Christoph J., Nair, Bijay, Waheed, Sarah, Sayed, Yazan Al, Chauhan, Nabeel, Ahmad, Nisar, Atrash, Shebli, Petty, Nathan, van Rhee, Frits, Crowley, John, and Barlogie, Bart
- Subjects
- *
MULTIPLE myeloma diagnosis , *THALIDOMIDE , *DISEASE incidence , *TRANSPLANTATION of organs, tissues, etc. , *DEXAMETHASONE , *CLINICAL trials - Abstract
Thalidomide and lenalidomide constitute an important part of effective myeloma therapy. Recent data from the Intergroup Francophone du Myelome, Cancer and Leukemia Group B, and Gruppo Italiano Malattle Ematologiche dell Adulto MM-015 trials suggest that lenalidomide main-tenance therapy is associated with a higher incidence of second primary malig-nancies (SPMs), including both hemato-logic and solid malignancies. In the pres-ent study, we analyzed data from the Total Therapy 2 (TT2) trial, along with the 2 Total Therapy 3 (TT3) trials. TT2 patients were assigned randomly to either a con-trol group (no thalidomide) or to the ex-perimental group (thalidomide during in-duction, between transplantations, and during consolidation and maintenance). The 2 TT3 trials used thalidomide and bortezomib during Induction, before and in consolidation after tandem melphalan-based transplantation; TT3A applied VTD (bortezomib, thalidomide, dexametha-sone) in the first year of maintenance and TD for 2 more years, whereas TT3B used VRD (bortezomib, lenalidomide, dexa-methasone) maintenance for 3 years. The cumulative incidence of SPMs did not differ significantly among the TT trial com-ponents when measured from enrollment (P = .78) or from initiation of mainte-nance (P = .82). However, a palrwise com-parison of the TT2 arms suggested a lower incidence of hematologic SPMs in the thalidomide maintenance arm (hazard ratio = 0.38; P = .09). These trials are registered at www.clinicaltrials.gov as NCT00573391 (TT2), NCT00081939 (TT3A), and NCT00572169 (TT3B). [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
17. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.
- Author
-
Usmani, Saad Z., Bona, Robert D., Chiosis, Gabriela, and Zihai Li
- Subjects
- *
TUMOR proteins , *HEAT shock proteins , *MITOCHONDRIAL membranes , *CANCER , *DRUGS , *MULTIPLE myeloma , *CELL lines , *CELL membranes , *CELL cycle , *BIOTECHNOLOGY - Abstract
Background: Heat shock protein 90 (HSP90) inhibitors have emerged as a promising class of anti-cancer drugs in both solid and hematologic malignancies. The HSP90 family includes the cytosolic HSP90 (HSP90AA1), the ER paralogue gp96 (HSP90B1) and the mitochondrial member TRAP1 (HSP90L). We evaluated the in vitro anti-tumor activity and mechanism of action of PU-H71, a novel purine scaffold HSP90 inhibitor in human multiple myeloma cell lines. Methods: Multiple human myeloma cell lines including cells that are resistant to corticosteroids and bortezimab were treated with PU-H71, followed by analysis of cell viability, cell cycle progression and apoptosis, by flow cytometry and caspase 3 immunoblot. Induction of unfolded protein response was studied by XBP-1 s immunoblot. The role of gp96 was further assessed by small hairpin RNA knockdown of gp96 before treatment with PU-H71. Results: PU-H71 has potent in vitro anti-myeloma activity in both drug-sensitive and drug-resistant cell lines. PU-H71 activates the unfolded protein response and induces caspase-dependent apoptosis. The stable gp96 knockdown human myeloma cell line was found to be more resistant to PU-H71 and other HSP90 inhibitors including 17-AAG and 17-DMAG, even though these cells are more sensitive to conventional anti-myeloma drugs. Conclusion: We conclude that PU-H71 is a promising drug for the treatment of myeloma. Our finding further suggests that PU-H71 and the geldanamycin analogues work in part by inhibiting the endoplasmic reticulum gp96 along with the cytosolic HSP90. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma.
- Author
-
Fonseca, Rafael, Usmani, Saad Z, Mehra, Maneesha, Slavcev, Mary, He, Jianming, Cote, Sarah, Lam, Annette, Ukropec, Jon, Maiese, Eric M, Nair, Sandhya, Potluri, Ravi, and Voorhees, Peter M
- Abstract
Background: For patients with multiple myeloma (MM), each additional line of therapy (LOT) is associated with lower response rates, shorter treatment duration and treatment-free intervals, and increased rates of toxicities and comorbidities. Here, we examine frontline treatment patterns, and attrition rates by LOT among newly diagnosed MM (NDMM) patients in the United States who were eligible or ineligible for autologous stem cell transplant (ASCT).Methods: Data were identified from three US patient-level databases collectively covering the period January 2000 to September 2018. Patients had an index diagnosis of MM on or after January 1, 2007, medical and prescription insurance coverage at diagnosis, a 1-year look-back period prior to the index diagnosis, no prior malignancies in the 1-year period before index diagnosis, and had received ≥1 LOT.Results: Among patients who did not receive ASCT (non-transplant; n = 22,062), 12,557 (57%) received only 1 LOT and 9505 (43%) received > 1 LOT. Patients receiving only 1 LOT were significantly older, had higher mean Charlson Comorbidity Index (CCI) scores, and higher incidences of comorbidities. Among the 2763 patients receiving ASCT, 2184 received > 1 LOT, and 579 (21%) received only 1 LOT (ie, ASCT was the last treatment). 1682 (61%) patients received induction therapy as frontline treatment, of whom 187 (11%) also received consolidation therapy. The latter group was younger than those who received only induction therapy, had lower mean CCI scores, and comparable or lower incidences of selected comorbidities. The most common frontline therapy for non-transplant and transplant-eligible patients was bortezomib/dexamethasone and bortezomib/lenalidomide/dexamethasone, respectively. Attrition rates across all LOTs were high for non-transplant patients (range, 43-57%) and transplant patients (range, 21-37%). Treatment duration decreased by LOT for non-transplant patients and was consistent across LOTs for transplant patients.Conclusions: In this analysis, a substantial proportion of patients with NDMM who received frontline therapy did not appear to receive a subsequent LOT. These high attrition rates underscore the need to use the most optimal treatment regimens upfront rather than reserving them for later LOTs in which the clinical benefit may decrease. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
19. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy.
- Author
-
Paul, Barry, Rodriguez, Cesar, and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma treatment , *B cells , *IMMUNOGLOBULINS , *PROTEASE inhibitors , *CANCER relapse , *IMMUNE system , *MONOCLONAL antibodies , *CELL receptors , *KILLER cells , *BIOTHERAPY - Abstract
With recent advances in myeloma therapy, patients can achieve long-term remissions, but eventually relapses will occur. Triple-class refractory myeloma (disease that is refractory to an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody) and penta-refractory myeloma (disease that is refractory to two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 antibody) are associated with a particularly poor prognosis, and novel treatments are desperately needed for these patients. Targeting B cell maturation antigen (BCMA), which is ubiquitously expressed on plasma cells, has emerged as a well-tolerated and highly efficacious strategy in patients with relapsed and refractory myeloma. Several mechanisms of targeting BCMA are currently under investigation, including antibody–drug conjugates, bispecific antibodies, and chimeric antigen receptor T cells and natural killer (NK) cells, all with unique side effect profiles. Early phase clinical trials showed unprecedented response rates in highly refractory myeloma patients, leading to the recent approvals of some of these agents. Still, many questions remain with regard to this target, including how best to target it, how to treat patients who have progressed on a BCMA-targeting therapy, and whether response rates will deepen if these agents are used in earlier lines of therapy. In this review, we examine the rationale for targeting BCMA and summarize the data for several agents across multiple classes of BCMA-targeting therapeutics, paying special attention to the diverse mechanisms and unique challenges of each therapeutic class. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
- Author
-
Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya M., Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Voorhees, Peter M., Usmani, Saad Z., and Richardson, Paul G.
- Subjects
- *
BLACK people , *DARATUMUMAB , *LENALIDOMIDE , *BORTEZOMIB , *HEALTH services accessibility - Abstract
Summary: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant‐eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment‐emergent adverse events. In summary, these findings suggest a benefit of D‐RVd front‐line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study.
- Author
-
Berdeja, Jesus G, Madduri, Deepu, Usmani, Saad Z, Jakubowiak, Andrzej, Agha, Mounzer, Cohen, Adam D, Stewart, A Keith, Hari, Parameswaran, Htut, Myo, Lesokhin, Alexander, Deol, Abhinav, Munshi, Nikhil C, O'Donnell, Elizabeth, Avigan, David, Singh, Indrajeet, Zudaire, Enrique, Yeh, Tzu-Min, Allred, Alicia J, Olyslager, Yunsi, and Banerjee, Arnob
- Subjects
- *
CHIMERIC antigen receptors , *MULTIPLE myeloma , *CYTOKINE release syndrome , *OVERALL survival , *SURVIVAL rate , *LYMPHOPENIA , *RESEARCH , *IMMUNIZATION , *CLINICAL trials , *RESEARCH methodology , *CELL receptors , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies - Abstract
Background: CARTITUDE-1 aimed to assess the safety and clinical activity of ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy with two B-cell maturation antigen-targeting single-domain antibodies, in patients with relapsed or refractory multiple myeloma with poor prognosis.Methods: This single-arm, open-label, phase 1b/2 study done at 16 centres in the USA enrolled patients aged 18 years or older with a diagnosis of multiple myeloma and an Eastern Cooperative Oncology Group performance status score of 0 or 1, who received 3 or more previous lines of therapy or were double-refractory to a proteasome inhibitor and an immunomodulatory drug, and had received a proteasome inhibitor, immunomodulatory drug, and anti-CD38 antibody. A single cilta-cel infusion (target dose 0·75 × 106 CAR-positive viable T cells per kg) was administered 5-7 days after start of lymphodepletion. The primary endpoints were safety and confirmation of the recommended phase 2 dose (phase 1b), and overall response rate (phase 2) in all patients who received treatment. Key secondary endpoints were duration of response and progression-free survival. This trial is registered with ClinicalTrials.gov, NCT03548207.Findings: Between July 16, 2018, and Oct 7, 2019, 113 patients were enrolled. 97 patients (29 in phase 1b and 68 in phase 2) received a cilta-cel infusion at the recommended phase 2 dose of 0·75 × 106 CAR-positive viable T cells per kg. As of the Sept 1, 2020 clinical cutoff, median follow-up was 12·4 months (IQR 10·6-15·2). 97 patients with a median of six previous therapies received cilta-cel. Overall response rate was 97% (95% CI 91·2-99·4; 94 of 97 patients); 65 (67%) achieved stringent complete response; time to first response was 1 month (IQR 0·9-1·0). Responses deepened over time. Median duration of response was not reached (95% CI 15·9-not estimable), neither was progression-free survival (16·8-not estimable). The 12-month progression-free rate was 77% (95% CI 66·0-84·3) and overall survival rate was 89% (80·2-93·5). Haematological adverse events were common; grade 3-4 haematological adverse events were neutropenia (92 [95%] of 97 patients), anaemia (66 [68%]), leukopenia (59 [61%]), thrombocytopenia (58 [60%]), and lymphopenia (48 [50%]). Cytokine release syndrome occurred in 92 (95%) of 97 patients (4% were grade 3 or 4); with median time to onset of 7·0 days (IQR 5-8) and median duration of 4·0 days (IQR 3-6). Cytokine release syndrome resolved in all except one with grade 5 cytokine release syndrome and haemophagocytic lymphohistiocytosis. CAR T-cell neurotoxicity occurred in 20 (21%) patients (9% were grade 3 or 4). 14 deaths occurred in the study; six due to treatment-related adverse events, five due to progressive disease, and three due to treatment-unrelated adverse events.Interpretation: A single cilta-cel infusion at the target dose of 0·75 × 106 CAR-positive viable T cells per kg led to early, deep, and durable responses in heavily pretreated patients with multiple myeloma with a manageable safety profile. The data from this study formed the basis for recent regulatory submissions.Funding: Janssen Research & Development and Legend Biotech. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
22. Melphalan Continues to Rock the Myeloma World
- Author
-
Usmani, Saad Z.
- Published
- 2013
- Full Text
- View/download PDF
23. Chemotherapy-Induced Thymus Hyperplasia Can Mimic Tumor Recurrence.
- Author
-
Halaweh, Osama, Usmani, Saad Z., and Bloom, Robert
- Subjects
- *
HYPERPLASIA , *THYMUS diseases , *CYSTS (Pathology) , *BREAST cancer , *CANCER in women - Abstract
The article presents the case of a 47-year-old woman who has an eight-centimeter breast mass. Stage III breast cancer was indicated by histology and staging. The study revealed the interval development of an anterior mediastinal mass that did not exist during a previous scan performed as part of her initial staging. An excisional biopsy, which was done to exclude the progression of her malignancy, showed that she had thymus hyperplasia.
- Published
- 2006
- Full Text
- View/download PDF
24. Bone marrow Ki‐67 index is of prognostic value in newly diagnosed multiple myeloma.
- Author
-
Atrash, Shebli, Robinson, Myra, Taneja, Alankrita, Paul, Barry, Cassetta, Kristen, Ndiaye, Ami, Varga, Cindy, Block, Jared, Lipford, Edward H., Smith, Elton T., McCall, Chad M., Thurston, Virginia, Foureau, David, Usmani, Saad Z., Voorhees, Peter M., and Bhutani, Manisha
- Subjects
- *
BONE marrow , *MULTIPLE myeloma , *KI-67 antigen , *PROGNOSIS , *PROGRESSION-free survival , *PLASMACYTOMA - Abstract
Background: Ki‐67 is an index of proliferative activity and is an established predictive and prognostic marker in multiple malignancies. However, its prognostic relevance in multiple myeloma (MM) is unclear. We investigated the relationship between Ki‐67 expression and survival outcomes in MM in the era of novel therapies. Methods: We interrogated our database to identify patients with MM, newly diagnosed between July 1, 2013 and December 31, 2020, with Ki‐67 expression assessed by immunohistochemistry (IHC) on bone marrow biopsies. Using an established threshold of 5% we defined Ki‐67low (≤5%) and Ki‐67high (>5%) subgroups for association with progression‐free survival (PFS) and overall survival (OS). Results: Of 167 patients included: 53 (31.7%) had Ki‐67high and 114 had Ki‐67low. More patients with R‐ISS 3 had Ki‐67high (22.2% vs. 9.7%). The gain of 1q21 was overrepresented in the Ki‐67high group (28% vs. 8%). Median PFS in the Ki‐67low group was 3.1 years, and in the Ki‐67high group 1.6 years (log‐rank p <.001, HR: 1.9). Median OS was not reached in the Ki‐67low vs. 4.8 years in the Ki‐67high cohort (HR: 1.9; log‐rank test: p =.018). In the multivariable modeling, after adjusting for other risk factors, HR for Ki‐67high versus Ki‐67low was 2.4 (p <.001) for PFS and 2.1 (p =.026) for OS. Conclusions: Our results demonstrate that a high Ki‐67 index (>5%) is an independent prognostic marker associated with worse OS and PFS in newly diagnosed MM. IHC staining for Ki‐67 on bone marrow biopsies could be easily adopted as a prognostic biomarker for MM in economically constrained healthcare settings. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
25. A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
- Author
-
Nath, Karthik, Shekarkhand, Tala, Salcedo, Meghan, Derkach, Andriy, Rueda, Siobhan, Chansakul, Aisara, Hulcrantz, Malin, Korde, Neha, Shah, Urvi A., Tan, Carlyn, Chung, David J., Lahoud, Oscar B., Hassoun, Hani, Lesokhin, Alexander M., Landau, Heather J., Shah, Gunjan, Scordo, Michael, Giralt, Sergio A., Usmani, Saad Z., and Roshal, Mikhail
- Subjects
- *
MULTIPLE myeloma , *DARATUMUMAB , *DISEASE remission , *CLINICAL trials , *PLASMACYTOMA ,BONE marrow examination - Abstract
At last follow-up, 5 (50%) patients remained on maintenance lenalidomide, and 5 (50%) patients received a subsequent line of therapy (note: three patients, in the absence of PD, continued on daratumumab beyond the six cycles). It is plausible that in standard-risk patients there may be a stable MRD clone without clinical consequence, leading to clinician and patient preferences to avoid interventions in the absence of a clinical relapse. Despite the improved complete response (CR) rates in multiple myeloma with newer therapies, most patients still relapse [[1]]. Although there was a third patient that converted to bone marrow MRD-negativity, this patient had serologic progressive disease (PD) at the time of response assessment and was deemed not to have achieved the primary end point. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF
26. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
- Author
-
Costa, Luciano J., Hari, Parameswaran, Berdeja, Jesus G., De Stefano, Valerio, Gay, Francesca, Hooper, Becky, Bartlett, Meaghan, Haltner, Anja, Rosta, Emily, Kumar, Shaji, Martin, Thomas, Mateos, Maria-Victoria, Moreau, Philippe, Usmani, Saad Z., Olyslager, Yunsi, Schecter, Jordan M., Roccia, Tito, Garrett, Ashraf, Lee, Sam, and Nesheiwat, Tonia
- Subjects
- *
MULTIPLE myeloma , *PHYSICIANS , *PROGRESSION-free survival , *OVERALL survival , *MULTIPLE comparisons (Statistics) , *CONFIDENCE intervals - Abstract
Objective: In the absence of head-to-head trials, indirect treatment comparisons (ITCs) between ciltacabtagene autoleucel (cilta-cel; in CARTITUDE-1) and treatments used in real-world clinical practice (physician's choice of treatment [PCT]), were previously conducted. We conducted multiple meta-analyses using available ITC data to consolidate the effectiveness of cilta-cel versus PCT for patients with triple-class exposed relapsed or refractory multiple myeloma (RRMM). Methods: Five ITCs were assessed for similarity to ensure robust comparisons using meta-analysis. Effectiveness outcomes were overall survival (OS), progression-free survival (PFS), time to next treatment (TTNT), and overall response rate (ORR). A robust variance estimator was used to account for the use of CARTITUDE-1 in each pairwise ITC. Analyses were conducted in both treated and enrolled populations of CARTITUDE-1. Results: Four ITCs were combined for evaluation of OS. Results were statistically significantly in favor of cilta-cel versus PCT in treated patients (hazard ratio [HR]: 0.24, 95% confidence interval [CI]: 0.22–0.26). Three ITCs were combined for evaluation of PFS and TTNT. Cilta-cel reduced the risk of progression and receiving a subsequent treatment by 80% (HR: 0.20 [95% CI: 0.06, 0.70]) and 83% (HR: 0.17 [95% CI: 0.12, 0.26]), respectively. Three ITCs were combined for evaluation of ORR. Cilta-cel increased the odds of achieving an overall response by 86-times versus PCT in treated patients. Findings were consistent in the enrolled populations and across sensitivity analyses. Conclusions: Evaluating multiple indirect comparisons, cilta-cel demonstrated a significantly superior advantage over PCT, highlighting its effectiveness as a therapy in patients with triple-class exposed RRMM. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
27. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
- Author
-
Lonial, Sagar, Weiss, Brendan M., Usmani, Saad Z., Singhal, Seema, Chari, Ajai, Bahlis, Nizar J., Belch, Andrew, Krishnan, Amrita, Vescio, Robert A., Mateos, Maria Victoria, Mazumder, Amitabha, Orlowski, Robert Z., Sutherland, Heather J., Bladé, Joan, Scott, Emma C., Oriol, Albert, Berdeja, Jesus, Gharibo, Mecide, Stevens, Don A., and LeBlanc, Richard
- Subjects
- *
MULTIPLE myeloma treatment , *MONOCLONAL antibodies , *PROTEASOME inhibitors , *STEM cell transplantation , *RANDOMIZED controlled trials , *PHYSIOLOGY , *THERAPEUTIC use of monoclonal antibodies , *ANTINEOPLASTIC agents , *CANCER relapse , *CLINICAL trials , *COMPARATIVE studies , *DRUG resistance in cancer cells , *DRUG administration , *RESEARCH methodology , *MEDICAL cooperation , *MULTIPLE myeloma , *PROGNOSIS , *RESEARCH , *RESEARCH funding , *EVALUATION research , *TREATMENT effectiveness , *KAPLAN-Meier estimator - Abstract
Background: New treatment options are needed for patients with multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory drugs. We assessed daratumumab, a novel CD38-targeted monoclonal antibody, in patients with refractory multiple myeloma.Methods: In this open-label, multicentre, phase 2 trial done in Canada, Spain, and the USA, patients (age ≥18 years) with multiple myeloma who were previously treated with at least three lines of therapy (including proteasome inhibitors and immunomodulatory drugs), or were refractory to both proteasome inhibitors and immunomodulatory drugs, were randomly allocated in a 1:1 ratio to receive intravenous daratumumab 8 mg/kg or 16 mg/kg in part 1 stage 1 of the study, to decide the dose for further assessment in part 2. Patients received 8 mg/kg every 4 weeks, or 16 mg/kg per week for 8 weeks (cycles 1 and 2), then every 2 weeks for 16 weeks (cycles 3-6), and then every 4 weeks thereafter (cycle 7 and higher). The allocation schedule was computer-generated and randomisation, with permuted blocks, was done centrally with an interactive web response system. In part 1 stage 2 and part 2, patients received 16 mg/kg dosed as in part 1 stage 1. The primary endpoint was overall response rate (partial response [PR] + very good PR + complete response [CR] + stringent CR). All patients who received at least one dose of daratumumab were included in the analysis. The trial is registered with ClinicalTrials.gov, number NCT01985126.Findings: The study is ongoing. In part 1 stage 1 of the study, 18 patients were randomly allocated to the 8 mg/kg group and 16 to the 16 mg/kg group. Findings are reported for the 106 patients who received daratumumab 16 mg/kg in parts 1 and 2. Patients received a median of five previous lines of therapy (range 2-14). 85 (80%) patients had previously received autologous stem cell transplantation, 101 (95%) were refractory to the most recent proteasome inhibitors and immunomodulatory drugs used, and 103 (97%) were refractory to the last line of therapy. Overall responses were noted in 31 patients (29.2%, 95% CI 20.8-38.9)-three (2.8%, 0.6-8.0) had a stringent CR, ten (9.4%, 4.6-16.7) had a very good PR, and 18 (17.0%, 10.4-25.5) had a PR. The median time to first response was 1.0 month (range 0.9-5.6). Median duration of response was 7.4 months (95% CI 5.5-not estimable) and progression-free survival was 3.7 months (95% CI 2.8-4.6). The 12-month overall survival was 64.8% (95% CI 51.2-75.5) and, at a subsequent cutoff, median overall survival was 17.5 months (95% CI 13.7-not estimable). Daratumumab was well tolerated; fatigue (42 [40%] patients) and anaemia (35 [33%]) of any grade were the most common adverse events. No drug-related adverse events led to treatment discontinuation.Interpretation: Daratumumab monotherapy showed encouraging efficacy in heavily pretreated and refractory patients with multiple myeloma, with a favourable safety profile in this population of patients.Funding: Janssen Research & Development. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
28. Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study.
- Author
-
Landgren, Ola, Weisel, Katja, Rosinol, Laura, Touzeau, Cyrille, Turgut, Mehmet, Hajek, Roman, Mollee, Peter, Kim, Jin Seok, Shu, Natalie, Hu, Xuguang, Li, Chuang, and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *SUBGROUP analysis (Experimental design) , *DARATUMUMAB , *PROGRESSION-free survival , *CYTOGENETICS - Abstract
CANDOR compared the safety/efficacy of carfilzomib with dexamethasone and daratumumab (KdD) to carfilzomib with dexamethasone (Kd) in adults with relapsed/refractory multiple myeloma (RRMM). This CANDOR subgroup analysis evaluated outcomes based on cytogenetic risk. Overall response rates (KdD vs. Kd) were 81% versus 56% in high‐risk and 87% versus 79% in standard‐risk groups. Median progression‐free survival was 11.2 versus 7.4 months in high‐risk (hazard ratio, 0.56 [95% CI, 0.34, 0.93]) and not reached versus 16.6 months in standard‐risk groups (0.56 [95% CI, 0.39, 0.80]). These data support the efficacy of KdD in RRMM treatment, including in patients with high‐risk cytogenetics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
- Author
-
Weisel, Katja, Martin, Thomas, Krishnan, Amrita, Jagannath, Sundar, Londhe, Anil, Nair, Sandhya, Diels, Joris, Vogel, Martin, Schecter, Jordan M., Banerjee, Arnob, Berdeja, Jesus G., Nesheiwat, Tonia, Garrett, Ashraf, Qi, Keqin, Valluri, Satish, Usmani, Saad Z., and Yong, Kwee
- Subjects
- *
MULTIPLE myeloma , *BORTEZOMIB , *PROTEASOME inhibitors , *PHYSICIANS , *CLINICAL trials , *TERMINATION of treatment , *DARATUMUMAB , *CD38 antigen - Abstract
Background and Objective: Ciltacabtagene autoleucel (cilta-cel) is a novel agent being investigated in the single-arm CARTITUDE-1 trial (NCT03548207) for patients with relapsed or refractory multiple myeloma who are triple-class exposed to an immunomodulatory drug, proteasome inhibitor, and an anti-CD38 monoclonal antibody. The objective of this study was to evaluate the comparative efficacy of cilta-cel vs physician's choice of treatment, as no head-to-head trials have been conducted. Methods: An external control arm for CARTITUDE-1 was created from patients in the long-term follow-up for three clinical trials of daratumumab (POLLUX, CASTOR, and EQUULEUS) who satisfied the eligibility criteria of CARTITUDE-1. These patients received physician's choice of treatment following the discontinuation of study drugs. Inverse probability of treatment weighting was used to align the external control and CARTITUDE-1 populations on important baseline characteristics. Overall response rate, complete response or better rate, progression-free survival, time to next treatment, and overall survival were assessed. Several sensitivity analyses were conducted. Results: After propensity score weighting, baseline characteristics were comparable between cohorts. Patients showed improved results with cilta-cel vs physician's choice of treatment: overall response rate (relative risk: 2.95 [95% confidence interval (CI) 2.27, 3.84; p < 0.0001]), complete response or better (relative risk: 111.70 [95% CI 29.08, 429.06; p < 0.0001]), progression-free survival (hazard ratio [HR]: 0.24 [95% CI 0.15, 0.37; p < 0.0001]), time to next treatment (HR: 0.14 [95% CI 0.09, 0.22; p < 0.0001]), and overall survival (HR: 0.21 [95% CI 0.13, 0.35; p < 0.0001]). Results were consistent across all sensitivity analyses. Conclusions: Cilta-cel showed superior efficacy compared with physician's choice of treatment, making it a promising new treatment option for patients with triple-class exposed relapsed or refractory multiple myeloma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Therapy-Related Myeloid Malignancies in Myeloma.
- Author
-
Papanikolaou, Xenofon, Barlogie, Bart, and Usmani, Saad Z.
- Subjects
- *
THERAPEUTIC complications , *MULTIPLE myeloma treatment , *LEUKEMIA treatment , *MYELOID leukemia , *ALKYLATING agents , *DNA topoisomerase II , *RADIOTHERAPY - Abstract
Therapy related myeloid malignancies are an increasingly recognized treatment complication in patients undergoing therapy for multiple myeloma. The main predisposing factors are the alkylating agents, topoisomerase II inhibitors and radiotherapy, but recently questions have been raised regarding the immunomodulatory agent lenalidomide. Little is known about the new antimyeloma agents in the context of therapy related myeloid malignancies. The duration of treatment and the time from diagnosis are the main contributing factors in alkylating induced myeloid malignancies which occur 5-10 years after treatment, chromosome 5 and 7 abnormalities being the characteristic finding. High dose therapy (HDT) does not seem to be a major contributing factor per se in multiple myeloma. In a number of large published series, all the factors related with therapy-induced myelodysplasia were defined prior to HDT. Topoisomerase II inhibitors induce mainly acute leukemias which invariably correlate with dysregulation of the MLL gene. Radiotherapy causes therapy related myelodysplasia if applied in bone marrow producing areas, especially if combined with chemotherapy. Therapy related myeloid malignancies generally herald a poor prognosis. Karyotypic abnormalities seem to be the main prognostic factor. In all cases the risk for therapy related myeloid malignancies drops sharply by 10 years after the treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
31. Health disparities experienced by Black and Hispanic Americans with multiple myeloma in the United States: a population-based study.
- Author
-
Al Hadidi, Samer, Dongarwar, Deepa, Salihu, Hamisu M., Kamble, Rammurti T., Lulla, Premal, Hill, LaQuisa C., Carrum, George, Ramos, Carlos A., Heslop, Helen E., and Usmani, Saad Z.
- Subjects
- *
HEALTH equity , *MULTIPLE myeloma , *HISPANIC Americans , *AFRICAN Americans , *HOSPITAL mortality - Abstract
Hispanics and non-Hispanic (NH)-Blacks continue to face numerous health disparities related to multiple myeloma (MM). We aimed to analyze trends of MM-related hospitalizations and incidence of in-hospital mortality with a 10-year cross-sectional analysis of inpatient hospitalizations. The prevalence of MM-related hospitalizations was higher in NH-Blacks compared to NH-Whites (476.0 vs. 305.6 per 100,000 hospitalizations, p <.001). MM-related in-hospital mortality was higher in Hispanics compared to NH-Whites and NH-Blacks (6.2 vs. 5.3%, p <.001). Using average annual percent change (AAPC), we found a statistically significant decline of in-hospital mortality among all MM patients except NH-Blacks (AAPC: −2.2, 95% confidence interval (CI) −4.7, 0.4, p =.47), who had the highest inpatient mortality in recent years. Multivariate analysis showed that NH-Blacks received fewer transplants, more blood product transfusions, fewer palliative care consults, less inpatient chemotherapy, and utilized more intensive care. Disparities in MM care for NH-Blacks and Hispanics continue to persist despite recent advancements in MM therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma.
- Author
-
Foureau, David, Bhutani, Manisha, Guo, Fei, Rigby, Katherine, Leonidas, Marina, Tjaden, Elise, Fox, Andee, Atrash, Shebli, Paul, Barry, Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *MASS spectrometry , *FLOW cytometry , *MONOCLONAL gammopathies , *MONOCLONAL antibodies , *IMMUNOGLOBULIN producing cells - Abstract
Keywords: mass spectrometry; multiple myeloma; NGF-MRD EN mass spectrometry multiple myeloma NGF-MRD 6933 6936 4 10/21/21 20211015 NES 211015 GLO:FU4O/15oct21:cam44254-toc-0001.jpg PHOTO (COLOR): . gl AKNOWLEDGEMENTS The authors thank Dr. Hazel O'Connor for providing valuable editing suggestions. To our knowledge, this is the first report comparing MALDI-TOF-MS and LC-MS serum M-protein analyses to bone marrow NGF at different sensitivity thresholds. Bone marrow aspirates were prospectively tested using standardized 2-tubes 8-colors NGF methods, and MRD status was established at three levels of sensitivity: 10 SP -4 sp , 10 SP -5 sp , and 10 SP -6 sp .4 Serum eluates were tested retrospectively by MALDI-TOF-MS and Ig-LC-MS for the presence of a serum M-protein using the same I m i / I z i as defined at baseline. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
33. Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy.
- Author
-
Quach, Hang, Nooka, Ajay, Samoylova, Olga, Venner, Christopher P., Kim, Kihyun, Facon, Thierry, Spencer, Andrew, Usmani, Saad Z., Grosicki, Sebastian, Suzuki, Kenshi, Delimpasi, Sosana, Weisel, Katja, Obreja, Mihaela, Zahlten‐Kumeli, Anita, and Mateos, Maria‐Victoria
- Subjects
- *
DARATUMUMAB , *MULTIPLE myeloma , *INTERACTIVE voice response (Telecommunication) - Abstract
For patients with one prior LOT, the PFS HR (95% CI) was 0-90 (0-48-1-70) for lenalidomide-naive patients, 0-30 (0-10-0-86) for lenalidomide-exposed patients and 0-11 (0-02-0-52) for lenalidomide-refractory patients. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Keywords: cancer; clinical studies; clinical trials; multiple myeloma EN cancer clinical studies clinical trials multiple myeloma 784 788 5 08/18/21 20210815 NES 210815 Bortezomib- and lenalidomide-based therapies have become standard front-line treatment for multiple myeloma (MM),1 resulting in many patients being refractory to bortezomib or lenalidomide at first relapse.2,3 This may negatively impact the efficacy of later lines of therapy (LOT)4 and makes optimal sequencing of MM therapies challenging. [Extracted from the article]
- Published
- 2021
- Full Text
- View/download PDF
34. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
- Author
-
Iida, Shinsuke, Ishikawa, Takayuki, Min, Chang Ki, Kim, Kihyun, Yeh, Su Peng, Usmani, Saad Z., Mateos, Maria-Victoria, Nahi, Hareth, Heuck, Christoph, Qin, Xiang, Parasrampuria, Dolly A., Gries, Katharine S., Qi, Ming, Bahlis, Nizar, and Ito, Shigeki
- Subjects
- *
ASIANS , *MULTIPLE myeloma , *SUBGROUP analysis (Experimental design) , *JAPANESE people , *PROTEASOME inhibitors , *DARATUMUMAB - Abstract
The phase 3 COLUMBA study demonstrated noninferiority of subcutaneous daratumumab (DARA SC) to intravenous daratumumab (DARA IV) in relapsed or refractory multiple myeloma. We present a subgroup analysis of Asian patients from COLUMBA. Eligible patients had ≥ 3 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory drug, or were double refractory. Co-primary endpoints were overall response rate (ORR) and maximum trough concentration (Ctrough). Secondary endpoints included rates of infusion-related reactions, progression-free survival, and patient-reported satisfaction with therapy. Sixty-seven Asian patients (DARA SC, n = 30; DARA IV, n = 37) were randomized, including 42 Japanese patients (DARA SC, n = 18; DARA IV, n = 24). Comparable ORRs for DARA SC versus DARA IV were seen in the Asian cohort (66.7% vs 43.2%) and Japanese-only cohort (61.1% vs 54.2%), including patients weighing ≤ 65 kg. Similarity of Ctrough was seen in both Asian and Japanese-only cohorts; the ratio of the geometric mean of the Ctrough concentrations for DARA SC/DARA IV was 143.96% (90% confidence interval (CI), 112.03–185.00%) and 148.02% (90% CI, 113.32–193.34%), respectively. The Asian cohort (both treatment groups) and Japanese-only cohort (DARA SC group) experienced higher rates of grade 3/4 cytopenias compared with the global COLUMBA population, occurring predominantly in patients of low bodyweight; no patients discontinued treatment due to cytopenias. The Cancer Therapy Satisfaction Questionnaire results generally favored DARA SC. In the Asian and Japanese-only cohorts, DARA SC was comparable to DARA IV. The efficacy, pharmacokinetic, safety, and satisfaction results were generally consistent with the global COLUMBA population regardless of patient bodyweight. ClinicalTrials.gov Identifier: NCT03277105 [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
35. Advances & future prospects in newly diagnosed multiple myeloma patients.
- Author
-
Hamadeh, Issam, Atrash, Shebli, Matusz Fisher, Ashley, Khan, Maham A., Diana Robinson, Jordan, Barry, Paul, and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma diagnosis , *STEM cell transplantation , *SCHEMA therapy - Abstract
The overall survival (OS) in multiple myeloma (MM) has almost quadrupled over the past 2 decades. This improvement could be attributed to the introduction of novel agents in the schema of therapy which includes the following phases: induction, high dose melphalan/stem cell transplant, optional posttransplant consolidation and maintenance (Barlogie Total‐Therapy schema). Because disease relapse is inevitable, additional treatment is generally needed to achieve remission. Emerging evidence suggests that assessment of minimal residual disease status following induction or autologous stem cell transplant could be predictive of duration of progression‐free survival as well as OS. In an effort to prolong duration of first remission, various drug combinations are being evaluated in the front‐line setting. The purpose of this paper is to provide a succint review of the current treatment paradigm of newly diagnosed MM and highlight the preliminary findings from some of the ongoing clinical trials which are likely to change current practice. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
36. Approaching the first relapse after autologous transplant in multiple myeloma.
- Author
-
Atrash, Shebli, Hamadeh, Issam, Matusz‐Fisher, Ashley, Ndiaye, Ami, Bhutani, Manisha, Voorhees, Peter M., Barry, Paul, and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma treatment , *AUTOGRAFTS , *CANCER relapse - Abstract
Multiple myeloma(MM) is an incurable plasma cell malignancy. Despite an improvement in OS over the past 2 decades, most patients do experience disease relapse. A subset of patients who experience an early disease relapse within 1‐2 years posttransplant, and considered functional high‐risk. Recent findings implicated high‐risk cytogenetic features and minimal residual disease as negative prognostic factors, each independently associated with early relapse among autologous stem cell transplant recipients(ASCT). The spectrum of disease relapse could range from asymptomatic/biochemical to more aggressive forms such as plasma cell leukemia. Hence, it is imperative that therapy be tailored based on these patterns of relapse upon presentation. The past few years have witnessed an explosion in the armamentarium of second‐line agents for the treatment of relapsed MM. Accordingly, choosing the optimal regimen has become quite challenging for the practicing clinician. In this review, we outline the approach for therapy selection, which takes into account underlying comorbid conditions, duration of response, presence of high‐risk features, etc Due to a better understanding of disease biology coupled with the advances in molecular techniques, the treatment landscape of relapsed MM (posttransplant) will most likely continue to evolve. Novel agents with distinct modes of action, such as immune therapies and novel oral agents are undergoing investigation in the relapsed setting. Once approved, these agents could potentially alter the course of the disease and possibly challenge the role of ASCT. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. Management of newly diagnosed transplant ineligible multiple myeloma.
- Author
-
Atrash, Shebli, Bhutani, Manisha, Paul, Barry, Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *STEM cell transplantation , *INFECTION prevention , *HEMATOLOGIC malignancies , *TRANSPLANTATION of organs, tissues, etc. , *PLASMACYTOMA - Abstract
Multiple myeloma (MM) is a chronically managed blood cancer with a median age of 69 years at the time of diagnosis. Although high dose melphalan and autologous stem cell transplantation (ASCT) remains a standard of care for eligible patients, more than half of the newly diagnosed MM patients are deemed ineligible due to comorbidities or complications of the disease by itself. In this setting, where ASCT is deemed inappropriate, patients could still achieve durable and deep responses if given the appropriate treatment plan. The key concepts of optimizing induction and maintenance strategies while minimizing side-effects are discussed in this review, especially in the context of employing novel agent combinations. It is important to understand the balance between safety and efficacy for each regimen, utilizing maintenance strategy and the best supportive care measures (bone health, infection prevention, and treatment, pain management, etc.). Here, we examine the evidence behind each of those principles and review results from clinical trials for transplant-ineligible (TI) MM. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
38. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study.
- Author
-
Dimopoulos, Meletios, Quach, Hang, Mateos, Maria-Victoria, Landgren, Ola, Leleu, Xavier, Siegel, David, Weisel, Katja, Yang, Hui, Klippel, Zandra, Zahlten-Kumeli, Anita, and Usmani, Saad Z
- Subjects
- *
MULTIPLE myeloma , *DEXAMETHASONE , *TERMINATION of treatment , *PROGRESSION-free survival , *TREATMENT duration , *DARATUMUMAB , *THERAPEUTIC use of antineoplastic agents , *RESEARCH , *INTRAVENOUS therapy , *CLINICAL trials , *OLIGOPEPTIDES , *CHRONIC diseases , *RESEARCH methodology , *CANCER relapse , *MONOCLONAL antibodies , *EVALUATION research , *MEDICAL cooperation , *TREATMENT effectiveness , *COMPARATIVE studies , *RANDOMIZED controlled trials - Abstract
Background: Lenalidomide and bortezomib frontline exposure has raised a growing need for novel treatments for patients with relapsed or refractory multiple myeloma. Carfilzomib in combination with daratumumab has shown substantial efficacy with tolerable safety in relapsed or refractory multiple myeloma in a phase 1 study. In this study, we aimed to compare the efficacy and safety of carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.Methods: In this randomised, multicentre, open-label, phase 3 study, 466 patients recruited from 102 sites across North America, Europe, Australia, and Asia with relapsed or refractory multiple myeloma were randomly assigned 2:1 to carfilzomib, dexamethasone, and daratumumab (KdD) or carfilzomib and dexamethasone (Kd). All patients received twice per week carfilzomib at 56 mg/m2 (20 mg/m2; days 1 and 2 during cycle 1). Daratumumab (8 mg/kg) was administered intravenously on days 1 and 2 of cycle 1 and at 16 mg/kg weekly for the remaining doses of the first two cycles, then every 2 weeks for four cycles (cycles 3-6), and every 4 weeks thereafter. Patients received 40 mg dexamethasone weekly (20 mg for patients ≥75 years old starting on the second week). The primary endpoint was progression-free survival assessed by intention to treat. Adverse events were assessed in the safety population. This trial (NCT03158688) is registered with ClinicalTrials.gov, and is active but not recruiting.Findings: Between June 13, 2017, and June 25, 2018, 466 patients of 569 assessed for eligibility were enrolled. After median follow-up of approximately 17 months, median progression-free survival was not reached in the KdD group versus 15·8 months in the Kd group (hazard ratio 0·63; 95% CI 0·46-0·85; p=0·0027). Median treatment duration was longer in the KdD versus the Kd group (70·1 vs 40·3 weeks). Grade 3 or higher adverse events were reported in 253 (82%) patients in the KdD group and 113 (74%) patients in the Kd group. The frequency of adverse events leading to treatment discontinuation was similar in both groups (KdD, 69 [22%]; Kd, 38 [25%]).Interpretation: KdD significantly prolonged progression-free survival versus Kd in patients with relapsed or refractory multiple myeloma and was associated with a favourable benefit-risk profile.Funding: Amgen. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
39. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
- Author
-
Lonial, Sagar, Lee, Hans C, Badros, Ashraf, Trudel, Suzanne, Nooka, Ajay K, Chari, Ajai, Abdallah, Al-Ola, Callander, Natalie, Lendvai, Nikoletta, Sborov, Douglas, Suvannasankha, Attaya, Weisel, Katja, Karlin, Lionel, Libby, Edward, Arnulf, Bertrand, Facon, Thierry, Hulin, Cyrille, Kortüm, K Martin, Rodríguez-Otero, Paula, and Usmani, Saad Z
- Subjects
- *
MULTIPLE myeloma , *PATIENT safety , *INTRAVENOUS therapy , *PROTEASOME inhibitors , *MONOCLONAL antibodies , *MONOCLONAL gammopathies , *AGAMMAGLOBULINEMIA - Abstract
Background: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study.Methods: DREAMM-2 is an open-label, two-arm, phase 2 study done at 58 multiple myeloma specialty centres in eight countries. Patients (aged ≥18 years) with relapsed or refractory multiple myeloma with disease progression after three or more lines of therapy and who were refractory to immunomodulatory drugs and proteasome inhibitors, and refractory or intolerant (or both) to an anti-CD38 monoclonal antibody with an Eastern Cooperative Oncology Group performance status of 0-2 were recruited, centrally randomly assigned (1:1) with permuted blocks (block size 4), and stratified by previous lines of therapy (≤4 vs >4) and cytogenetic features to receive 2·5 mg/kg or 3·4 mg/kg belantamab mafodotin via intravenous infusion every 3 weeks on day 1 of each cycle until disease progression or unacceptable toxicity. The intention-to-treat population comprised all randomised patients, regardless of treatment administration. The safety population comprised all patients who received at least one dose of belantamab mafodotin. The primary outcome was the proportion of randomly assigned patients in the intention-to-treat population who achieved an overall response, as assessed by an independent review committee. This study is registered with ClinicalTrials.gov, NCT03525678, and is ongoing.Findings: Between June 18, 2018, and Jan 2, 2019, 293 patients were screened and 196 were included in the intention-to-treat population (97 in the 2·5 mg/kg cohort and 99 in the 3·4 mg/kg cohort). As of June 21, 2019 (the primary analysis data cutoff date), 30 (31%; 97·5% CI 20·8-42·6) of 97 patients in the 2·5 mg/kg cohort and 34 (34%; 23·9-46·0) of 99 patients in the 3·4 mg/kg cohort achieved an overall response. The most common grade 3-4 adverse events in the safety population were keratopathy (in 26 [27%] of 95 patients in the 2·5 mg/kg cohort and 21 [21%] of 99 patients in the 3·4 mg/kg cohort), thrombocytopenia (19 [20%] and 33 [33%]), and anaemia (19 [20%] and 25 [25%]); 38 (40%) of 95 patients in the 2·5 mg/kg cohort and 47 (47%) of 99 in the 3·4 mg/kg cohort reported serious adverse events. Two deaths were potentially treatment related (one case of sepsis in the 2·5 mg/kg cohort and one case of haemophagocytic lymphohistiocytosis in the 3·4 mg/kg cohort).Interpretation: Single-agent belantamab mafodotin shows anti-myeloma activity with a manageable safety profile in patients with relapsed or refractory multiple myeloma.Funding: GlaxoSmithKline. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
40. Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses.
- Author
-
Arnall, Justin R., Moore, Donald C., Hill, Hailey L., Griffin, Sarah, Mueller, Maxine K., Lavery, Lesli A., Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
PATIENT compliance , *MULTIPLE myeloma - Abstract
A retrospective chart review of patients at our institution who received split-dose daratumumab between January 2015 and August 2018 was conducted to assess the impact of a split-dose daratumumab protocol on the feasibility of outpatient administration. One patient experienced a grade 3 IRR on day 1 of treatment; the patient then received day 2 daratumumab 8 mg/kg without any recurrence of IRR. Twelve patients (92%) continued daratumumab following split dosing; one patient experienced rapid disease progression that resulted in the patient electing to seek hospice treatment. Patient adherence to the prescribed treatment regimen should continue to be weighed, but for this patient lack of adherence was not overall detrimental to his tolerability to daratumumab. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
41. Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma.
- Author
-
Hussain, M. Junaid, Robinson, Myra M., Hamadeh, Issam, Arnall, Justin, Bhutani, Manisha, Atrash, Shebli, Friend, Reed, Pineda‐Roman, Mauricio, Symanowski, James T., Usmani, Saad Z., and Voorhees, Peter M.
- Subjects
- *
MULTIPLE myeloma , *THALIDOMIDE , *BORTEZOMIB , *T helper cells , *CYTOTOXIC T cells , *KILLER cells - Abstract
The article focuses on the role of Daratumumab, pomalidomide and dexamethasone (Pd) combination therapy for the treatment of relapsed and refractory multiple myeloma. It mentions the addition of daratumumab to the Pd backbone (DaraPd) for the patients with relapsed and refractory multiple myelom and also discussions on daratumumab that depletes levels of CD38 (cluster of differentiation 38).
- Published
- 2019
- Full Text
- View/download PDF
42. Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation.
- Author
-
Copelan, Olivia R., Sanikommu, Srinivasa R., Trivedi, Jigar S., Butler, Candace, Ai, Jing, Ragon, Brittany K., Jacobs, Ryan, Knight, Thomas G., Usmani, Saad Z., Grunwald, Michael R., Ghosh, Nilanjan, Symanowski, James T., Shahid, Zainab, Clark, Peter E., and He, Jiaxian
- Subjects
- *
BK virus , *CYSTITIS , *CELL transplantation , *TRANSPLANTATION of organs, tissues, etc. , *IMMUNODEFICIENCY , *GRAFT versus host disease , *DNA mismatch repair - Abstract
Highlights • Hemorrhagic cystitis occurs more frequently following haploidentical donor transplantation compared with matched related donor transplantation. • This higher frequency occurs despite the receipt of identical graft-versus-host disease prevention. • The grater susceptibility appears related to the inherent immune deficiency of HLA mismatch. ABSTRACT Hemorrhagic cystitis (HC) is a common and important complication of allogeneic hematopoietic cell transplantation (HCT). Reactivation of BK virus is its most common cause. The more intense immunosuppressive regimens administered to recipients of grafts from alternative donors have been reported to account for the increased susceptibility to HC in this population. This study compares patients undergoing HCT with either a haploidentical donor or a matched related donor, all of whom received identical immunosuppression with a post-transplantation cyclophosphamide-based regimen. The incidence of HC was significantly higher in the patients receiving a haploidentical graft (P =.01). The higher incidence of HC in haploidentical graft recipients is therefore directly related to the inherent immune deficiency that follows HLA-mismatched transplantation, independent of the intensity of pharmacologic immunosuppression. This finding carries significant clinical impact for the prevention and treatment of HC in haploidentical graft recipients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
43. Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma.
- Author
-
Gopalakrishnan, Sathish, D'Souza, Anita, Scott, Emma, Fraser, Raphael, Davila, Omar, Shah, Nina, Gale, Robert Peter, Kamble, Rammurti, Diaz, Miguel Angel, Lazarus, Hillard M., Savani, Bipin N., Hildebrandt, Gerhard C., Solh, Melhem, Freytes, Cesar O., Lee, Cindy, Kyle, Robert A, Usmani, Saad Z., Ganguly, Siddhartha, Assal, Amer, and Berdeja, Jesus
- Subjects
- *
AUTOTRANSPLANTATION , *MULTIPLE myeloma , *CELL transplantation , *LACTATE dehydrogenase , *GENETIC markers , *COMORBIDITY , *MEDICAL databases - Abstract
Abstract The revised International Staging System (R-ISS) combines ISS with genetic markers and lactate dehydrogenase and can prognosticate newly diagnosed multiple myeloma (MM). Early relapse (<24 months) after upfront autologous hematopoietic cell transplantation (AHCT) strongly predicts inferior overall survival (OS). We examined the ability of R-ISS in predicting early relapse and its independent prognostic effect on postrelapse survival after an early relapse. Using the Center for International Blood and Marrow Transplant Research database we identified MM patients receiving first AHCT within 18 months after diagnosis with available R-ISS stage at diagnosis (n = 628). Relative risks of relapse/progression, progression-free survival (PFS), and OS were calculated with the R-ISS group as a predictor in multivariate analysis. Among early relapsers, postrelapse survival was tested to identify factors affecting postrelapse OS. The cumulative incidence of early relapse was 23%, 39%, and 50% for R-ISS I, R-ISS II, and R-ISS III, respectively (P <.001). Shorter PFS and OS were seen with higher stage R-ISS. R-ISS was independently predictive for inferior postrelapse OS among early relapsers, as was the presence of ≥3 comorbidities and the use of ≥2 induction chemotherapy lines. R-ISS stage at diagnosis predicts early post-AHCT relapse and independently affects postrelapse survival among early relapsers. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma.
- Author
-
Bhutani, Manisha, Foureau, David, Zhang, Qing, Robinson, Myra, Wynn, Adina S., Steuerwald, Nury M., Druhan, Lawrence J., Guo, Fei, Rigby, Katherine, Turner, Mitchell, Slaughter, Daniel, Friend, Reed, Atrash, Shebli, Symanowski, James T., Avalos, Belinda R., Copelan, Edward A., Voorhees, Peter M., and Usmani, Saad Z.
- Subjects
- *
MULTIPLE myeloma , *KILLER cells , *STEM cell transplantation , *T cells , *BONE marrow , *HEMATOPOIETIC system - Abstract
Highlights • NK, NK-T, and T cell peripheral immunotypes differ between MRDpos and MRDneg MM. • Lenalidomide maintenance has pleiotropic effects on NK, NK-T, and T cell immunotypes. • Peripheral T cells skew to an exhausted state during maintenance in MRDpos patients. Abstract Data indicate reversal of immune dysfunction with active treatment; however, the precise contribution of specific immune effector and immune suppressor components to achieve a minimal residual disease (MRD) state and immunomodulatory drug–mediated immunomodulatory effects in multiple myeloma (MM) patients remains poorly understood. In this prospective proof-of-principle study we sought to determine the dynamic alterations in natural killer (NK), NK-T, and T cells, including maturation and activating/inhibitory repertoire associated with MRDpos versus MRDneg status after autologous stem cell transplantation (ASCT) and during lenalidomide-based maintenance therapy. Of the 46MM patients enrolled, 36 had bone marrow MRD assessment 60+ days post-ASCT, 30 had longitudinal blood immunotyping during maintenance (pretherapy and after cycles 1, 3, and 6), and 20 had both MRD assessment and longitudinal immunotyping. Multicolor flow cytometry was used for MRD and immunotyping. Although the absolute number of NK cells was significantly lower in patients with MRDpos response, phenotypically NK cells in these patients displayed higher expression of activating receptors KIRDS4 and decreased expression of inhibitory molecules NKG2A compared with the MRDneg group. Furthermore, we observed significantly lower frequencies of T cells displaying KIR3DL1 in MRDpos versus MRDneg patients. Longitudinal immunotyping during lenalidomide maintenance showed loss of mature NK effector function, augmentation of NK-T effector function, and acquisition of PD1 independent anergic state. Our findings also suggest skewing of T cells toward an exhausted state during the maintenance phase in MRDpos patients. Put together, these observations provide a distinctive signature for MRDneg and MRDpos groups. These data support exploration of immune profiling in prospective clinical trials according to MRD-defined responses to identify patients that may benefit from maintenance intensification/modification or maintenance withdrawal. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
45. Impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma.
- Author
-
Donk, Niels W. C. J., Casneuf, Tineke, Di Cara, Alessandro, Parren, Paul W., Zweegman, Sonja, Kessel, Berris, Lokhorst, Henk M., Usmani, Saad Z., Lonial, Sagar, Richardson, Paul G., Chiu, Christopher, Mutis, Tuna, Nijhof, Inger S., and Sasser, A. Kate
- Abstract
The article informs on a study for analysing the impact of Fc gamma receptor polymorphisms on efficacy and safety of daratumumab in relapsed/refractory multiple myeloma. It examines effect of Fc portion of IgG polymorphisms on response, survival, and infusion-related reactions in multiple myeloma patients treated with daratumumab drug as single agent in the GEN501 and SIRIUS studies.
- Published
- 2019
- Full Text
- View/download PDF
46. Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups.
- Author
-
Scott, Emma C., Hari, Parameswaran, Kumar, Sathish, Fraser, Raphael, Davila, Omar, Shah, Nina, Gale, Robert Peter, Diaz, Miguel Angel, Agrawal, Vaibhav, Cornell, Robert F., Ganguly, Siddhartha, Akpek, Gorgun, Freytes, Cesar, Hashmi, Shahrukh, Malek, Ehsan, Kamble, Rammurti T., Lazarus, Hillard, Solh, Melhem, Usmani, Saad Z., and Kanate, Abraham S.
- Subjects
- *
MULTIPLE myeloma , *HEMATOPOIETIC stem cell transplantation , *BONE marrow transplantation , *LACTATE dehydrogenase , *CYTOGENETICS - Abstract
Highlights • The authors report a comparison of 3 contemporaneous staging systems for newly diagnosed multiple myeloma patients undergoing autologous hematopoietic cell transplantation using the Center for International Blood and Marrow Transplant Research database. • The Revised International Staging System is the most optimal staging system. • The authors recommend that serum lactate dehydrogenase and cytogenetic data be performed on every multiple myeloma patient at diagnosis to allow accurate prognostication. Abstract The Revised International Staging System (R-ISS) and the International Myeloma Working Group 2014 (IMWG 2014) are newer staging systems used to prognosticate multiple myeloma (MM) outcomes. We hypothesized that these would provide better prognostic differentiation for newly diagnosed multiple myeloma (MM) compared with ISS. We analyzed the Center for International Blood and Marrow Transplant Research database from 2008 to 2014 to compare the 3 systems (N = 628) among newly diagnosed MM patients undergoing upfront autologous hematopoietic cell transplantation (AHCT). The median follow-up of survivors was 48 (range, 3 to 99) months. The R-ISS provided the greatest differentiation between survival curves for each stage (for overall survival [OS], the differentiation was 1.74 using the R-ISS, 1.58 using ISS, and 1.60 using the IMWG 2014). Univariate analyses at 3 years for OS showed R-ISS I at 88% (95% confidence interval [CI], 83% to 93%), II at 75% (95% CI, 70% to 80%), and III at 56% (95% CI, 3% to 69%; P <.001). An integrated Brier score function demonstrated the R-ISS had the best prediction for PFS, though all systems had similar prediction for OS. Among available systems, the R-ISS is the most optimal among available prognostic tools for newly diagnosed MM undergoing AHCT. We recommend that serum lactate dehydrogenase and cytogenetic data be performed on every MM patient at diagnosis to allow accurate prognostication. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
47. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
- Author
-
Chari, Ajai, Lonial, Sagar, Mark, Tomer M., Krishnan, Amrita Y., Stockerl‐Goldstein, Keith E., Usmani, Saad Z., Londhe, Anil, Etheredge, Delores, Fleming, Sarah, Liu, Baolian, Ukropec, Jon, Lin, Thomas S., Jagannath, Sundar, Nooka, Ajay K., and Stockerl-Goldstein, Keith E
- Subjects
- *
MULTIPLE myeloma , *MONOCLONAL antibodies , *ADVERSE health care events , *THROMBOCYTOPENIA , *ANEMIA , *MONTELUKAST - Abstract
Background: Daratumumab is a human CD38-directed monoclonal antibody indicated for the treatment of relapsed and refractory multiple myeloma (MM).Methods: A multicenter, open-label treatment protocol provided early access to daratumumab for patients who had progressive MM after they received ≥3 prior lines of therapy that included a proteasome inhibitor and an immunomodulatory agent or if they were refractory to both a proteasome inhibitor and an immunomodulatory agent. Patients received daratumumab 16 mg/kg weekly for 8 weeks, every other week for 16 weeks, and monthly until they developed disease progression, unacceptable toxicity, or 60 days after the drug gained US approval. Treatment-emergent grade ≥3 adverse events (AEs), serious AEs, and AEs of special interest were collected.Results: Three hundred forty-eight patients were enrolled at 39 US sites between June and December 2015. Patients received study therapy for a median of 1.9 months (range, 0.03-6.0 months). Fifty-two percent of patients transitioned to commercially-available daratumumab and 37% discontinued because of progressive disease. Grade ≥3 AEs occurred in 50% of patients, including thrombocytopenia (15%) and anemia (14%). Serious AEs occurred in 35% of patients (12% were drug-related), including infections (11%). Infusion reactions occurred in 56%, 2%, and 2% of patients during the first, second, and all subsequent infusions, respectively; respiratory symptoms (cough, dyspnea, throat irritation, nasal congestion) were common. The infusion reaction rate for the first infusion was 38% in 50 patients at 2 sites who received montelukast as premedication for their first infusion and 59% in patients who did not receive montelukast.Conclusions: The current findings are consistent with previously reported trials and confirm the safety profile of daratumumab in heavily pretreated US patients who have relapsed or refractory MM. Cancer 2018;124:000-000. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
48. Phase 1 trial of ibrutinib and carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma.
- Author
-
Chari, Ajai, Larson, Sarah, Holkova, Beata, Cornell, Robert F., Gasparetto, Cristina, Karanes, Chatchada, Matous, Jeffrey V., Niesvizky, Ruben, Valent, Jason, Lunning, Matthew, Usmani, Saad Z., Anderson, Larry D., Chang, Lipo, Lee, Yihua, Pak, Yvonne, Salman, Zeena, Graef, Thorsten, Bilotti, Elizabeth, and Chhabra, Saurabh
- Subjects
- *
IBRUTINIB , *PROTEASOME inhibitors , *HEMATOLOGIC malignancies , *CANCER relapse , *MULTIPLE myeloma - Abstract
This phase 1, dose-finding study investigated ibrutinib and carfilzomib ± dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (≥2 lines of therapy including bortezomib and an immunomodulatory agent). Of 43 patients enrolled, 74% were refractory to bortezomib and 23% had high-risk cytogenetics. No dose-limiting toxicities were observed. The recommended phase 2 dose was ibrutinib 840 mg and carfilzomib 36 mg/m2 with dexamethasone. The most common ≥ grade 3 (>10%) treatment-emergent adverse events were hypertension, anemia, pneumonia, fatigue, diarrhea, and thrombocytopenia. Overall response rate was 67% (very good partial response, 21%; stringent complete response, 2%), with an additional 9% minimal response. Median progression-free survival was 7.2 months and was not inferior in refractory nor high-risk patients. Median overall survival was not reached. Ibrutinib plus carfilzomib demonstrated encouraging responses with a manageable safety profile in this advanced population. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
49. BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee.
- Author
-
Holstein, Sarah A., Avet-Loiseau, Hervé, Hahn, Theresa, Ho, Christine M., Lohr, Jens G., Munshi, Nikhil C., Paiva, Bruno, Pasquini, Marcelo C., Jr.Tario, Joseph D., Usmani, Saad Z., Wallace, Paul K., Weisel, Katja, and McCarthy, Philip L.
- Subjects
- *
BONE marrow transplantation , *BLOOD transfusion , *HEMATOLOGY , *CLINICAL trials , *IMMUNITY , *MEDICAL societies - Abstract
The Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling was convened on December 1, 2016 at the American Society of Hematology meeting to discuss the emerging data and technologies for minimal residual disease assessment and immune profiling in myeloma. Particular emphasis was placed on developing strategies to incorporate these techniques into clinical trial design. This document reviews the literature, summarizes the topics discussed in the workshop, and provides recommendations for integration of these techniques into future clinical trial design. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
50. Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival.
- Author
-
Htut, Myo, D'Souza, Anita, Krishnan, Amrita, Bruno, Benedetto, Zhang, Mei-Jie, Fei, Mingwei, Diaz, Miguel Angel, Copelan, Edward, Ganguly, Siddhartha, Hamadani, Mehdi, Kharfan-Dabaja, Mohamed, Lazarus, Hillard, Lee, Cindy, Meehan, Kenneth, Nishihori, Taiga, Saad, Ayman, Seo, Sachiko, Ramanathan, Muthalagu, Usmani, Saad Z., and Gasparetto, Christina
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma treatment , *CANCER immunotherapy , *MONOCLONAL antibodies , *SURVIVAL analysis (Biometry) , *FOLLOW-up studies (Medicine) - Abstract
We compared postrelapse overall survival (OS) after autologous/allogeneic (auto/allo) versus tandem autologous (auto/auto) hematopoietic cell transplantation (HCT) in patients with multiple myeloma (MM). Postrelapse survival of patients receiving an auto/auto or auto/allo HCT for MM and prospectively reported to the Center for International Blood and Marrow Transplant Research between 2000 and 2010 were analyzed. Relapse occurred in 404 patients (72.4%) in the auto/auto group and in 178 patients (67.4%) in the auto/allo group after a median follow-up of 8.5 years. Relapse occurred before 6 months after a second HCT in 46% of the auto/allo patients, compared with 26% of the auto/auto patients. The 6-year postrelapse survival was better in the auto/allo group compared with the auto/auto group (44% versus 35%; P = .05). Mortality due to MM was 69% (n = 101) in the auto/allo group and 83% (n = 229) deaths in auto/auto group. In multivariate analysis, both cohorts had a similar risk of death in the first year after relapse (hazard ratio [HR], .72; P = .12); however, for time points beyond 12 months after relapse, overall survival was superior in the auto/allo cohort (HR for death in auto/auto =1.55; P = .005). Other factors associated with superior survival were enrollment in a clinical trial for HCT, male sex, and use of novel agents at induction before HCT. Our findings shown superior survival afterrelapse in auto/allo HCT recipients compared with auto/auto HCT recipients. This likely reflects a better response to salvage therapy, such as immunomodulatory drugs, potentiated by a donor-derived immunologic milieu. Further augmentation of the post-allo-HCT immune system with new immunotherapies, such as monoclonal antibodies, checkpoint inhibitors, and others, merit investigation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.